Iguratimod for the treatment of rheumatoid arthritis in Japan

Expert Review of Clinical Immunology
Keiichi TanakaMasako Hara

Abstract

Iguratimod (IGU), a small-molecule compound, was developed as a disease-modifying antirheumatic drug in Japan. The pharmacological studies showed that inhibition of the production of cytokines and immunoglobulins mainly contributes to its improvement effect on animal arthritis models. The first clinical study of IGU in Japanese patients with rheumatoid arthritis was started in 1992 and Phase III studies were started in 1998. From the results of Phase II studies, a dose-escalating regimen was recommended to relieve the side effects. In a double-blind study comparing the efficacy and safety of the drug with those of placebo and salazosulfapyridine, it was confirmed that IGU was superior to placebo and was not inferior to salazosulfapyridine. Furthermore, a double-blind controlled trial of IGU in combination with methotrexate revealed an efficacious and manageable safety profile. IGU would be widely used as a new option for rheumatoid arthritis treatment and combination drug with methotrexate.

References

Nov 30, 2000·Arthritis Research·C Benoist, D Mathis
Feb 13, 2002·Arthritis and Rheumatism·UNKNOWN American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines
May 16, 2002·Current Rheumatology Reports·Ulf Müller-LadnerSteffen Gay
Jun 13, 2002·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Y AikawaK Tanaka
Jul 11, 2008·Immunological Reviews·Marc Feldmann, Sir Ravinder N Maini
Nov 1, 2008·Current Rheumatology Reviews·Zafar Rasheed, Tariq M Haqqi
Mar 11, 2010·Annals of the Rheumatic Diseases·Josef S SmolenUNKNOWN T2T Expert Committee
Sep 28, 2010·Lancet·David L ScottTom W J Huizinga
Feb 5, 2011·International Archives of Allergy and Immunology·Qingtong WangWei Wei
Dec 22, 2011·Nihon Hoshasen Gijutsu Gakkai zasshi·UNKNOWN Japan Industries Association of Radiological Systems, Facility Design Group Standardization Committee
Jun 13, 2013·The New England Journal of Medicine·James R O'DellUNKNOWN CSP 551 RACAT Investigators
Oct 15, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Qiong LuoQiang Xu
Jul 30, 2014·Modern Rheumatology·Koichi OkamuraKenji Takagishi

❮ Previous
Next ❯

Citations

Jun 3, 2016·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Tetsuya YamamotoKeiichi Tanaka
Sep 7, 2017·Gut·Silvio DaneseLaurent Peyrin-Biroulet
Aug 1, 2018·Annals of the Rheumatic Diseases·Nadia Mt RoodenrijsJohannes Wg Jacobs
Mar 17, 2020·Frontiers in Pharmacology·Sisi XieFen Li
Jun 15, 2017·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·K MorimotoKeiichi Tanaka
Dec 12, 2020·International Immunopharmacology·Chang-Hong LiJin-Xia Zhao
Jan 7, 2021·Therapeutic Advances in Musculoskeletal Disease·Julien BlaessRenaud Felten
Apr 4, 2021·International Immunopharmacology·Yuan XiaXiangpei Li
Jun 24, 2021·Journal of Orthopaedic Surgery and Research·Shan CongLi Luo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.